Can radiation boost immunotherapy's power against hard-to-treat stomach cancers?

NCT ID NCT03610711

Ongoing Knowledge-focused Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding targeted radiation to immunotherapy drugs (nivolumab with or without relatlimab) is safe and can boost the immune system's attack on advanced stomach or esophageal cancer. About 21 adults with limited metastatic disease will receive radiation to some tumors followed by immunotherapy. The main goal is to measure immune cell changes in non-irradiated tumors, not to cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL CANCER IMMUNE CHECKPOINT INHIBITION

Contacts and locations

Show contact details

Locations

Alleghany Health Network

Pittsburgh, Pennsylvania, 15212, United States
Baylor University

Dallas, Texas, 75246, United States
Johns Hopkins University

Baltimore, Maryland, 21287, United States